Drug Profile


Alternative Names: FMX-8

Latest Information Update: 13 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FerruMax Pharmaceuticals
  • Class Antianaemics; Recombinant fusion proteins
  • Mechanism of Action Hepcidin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 12 May 2017 Discontinued - Phase-II for Anaemia in USA (IV), because no recent reports on development were identified further to phase II trial termination
  • 15 Dec 2016 Biomarkers information updated
  • 17 Jul 2014 FerruMax Pharmaceuticals plans a phase 0 trial in Anaemia in USA (NCT02228655)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top